Some studies have demonstrated a survival benefit for contralateral RRM in women with BRCA1/2‐associated breast cancer (Evans et al., 2013; Heemskerk‐Gerritsen et al., 2015; Metcalfe et al., 2014). This evidence concerns the gene BRCA1 and breast carcinoma.